Novo Nordisk’s new Denmark site will produce drugs for rare diseases, such as hemophilias. Separately, the pharma giant said all regulatory conditions have been met for Novo Holdings’ acquisition of Catalent, which will bring to Novo Nordisk three manufacturing sites for GLP-1 medications.
The post Novo Nordisk Adds to Manufacturing Capacity, Pumping Billions Into New Rare Disease Site appeared first on MedCity News.
